Other complications ‐ not reported · Patients with rheumatoid shoulder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Haemoglobin (g/dL) · participants were of any age or sex and from any country, regardless of baseline iron and iodine status
1 finding from 1 review
Urinary iodine concentration (non‐RCT) · participants were of any age or sex and from any country, regardless of baseline iron and iodine status
1 finding from 1 review
Blood pressure · participants were of any age or sex and from any country, regardless of baseline iron and iodine status
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ferritin (µg/L) · participants were of any age or sex and from any country, regardless of baseline iron and iodine status
1 finding from 1 review
Transferrin receptor concentration (mg/L) · participants were of any age or sex and from any country, regardless of baseline iron and iodine status
1 finding from 1 review
Anaemia prevalence · participants were of any age or sex and from any country, regardless of baseline iron and iodine status
Fortification of salt with iron and iodine probably leads to lower prevalence of anaemia compared with fortification of salt with iodine (moderate certainty).
1 finding from 1 review
Prevalence of iron deficiency anaemia · participants were of any age or sex and from any country, regardless of baseline iron and iodine status
Fortification of salt with iron and iodine may leads to lower prevalence of iron deficiency anaemia compared with fortification of salt with iodine (low certainty).
1 finding from 1 review
Intraperitoneal pain (NRS; higher = more pain) · women undergoing PPTL under local anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse events within 48 hours post operation · women undergoing PPTL under local anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Number of women requiring rescue medication · women undergoing PPTL under local anaesthesia
Combination of lidocaine intraperitoneal instillation plus… showed no clear difference in number of women requiring rescue medication compared with lidocaine intraperitoneal instillation alone (low certainty).
1 finding from 1 review
RR 0.5 [0.1, 2.43]
Studies not reported
Low
Access thrombosis/vascular complication · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
Scheduled surveillance showed no clear difference in risk of access thrombosis compared with clinical monitoring alone (moderate certainty).
1 finding from 1 review
Rate of angiograms · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
Scheduled surveillance may leads to higher rate of angiograms compared with clinical monitoring alone (low certainty).
1 finding from 1 review
Risk of access loss · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
Scheduled surveillance showed no clear difference in risk of access loss compared with clinical monitoring alone (moderate certainty).
1 finding from 1 review
All‐cause mortality · people receiving haemodialysis to treat kidney failure and using a functioning AV access for haemodialysis.
Scheduled surveillance showed no clear difference in mortality compared with clinical monitoring alone (low certainty).
1 finding from 1 review
All‐cause mortality: at 3 years · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
1 finding from 1 review
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Health‐related quality of life · primary hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).
1 finding from 1 review